TW202039538A - 自殺基因 - Google Patents

自殺基因 Download PDF

Info

Publication number
TW202039538A
TW202039538A TW108141960A TW108141960A TW202039538A TW 202039538 A TW202039538 A TW 202039538A TW 108141960 A TW108141960 A TW 108141960A TW 108141960 A TW108141960 A TW 108141960A TW 202039538 A TW202039538 A TW 202039538A
Authority
TW
Taiwan
Prior art keywords
tnf
cells
vector
mutant
composition
Prior art date
Application number
TW108141960A
Other languages
English (en)
Chinese (zh)
Inventor
凱蒂 瑞分尼
依麗莎白 J 須帕爾
Original Assignee
美國德州系統大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68848450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202039538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美國德州系統大學評議委員會 filed Critical 美國德州系統大學評議委員會
Publication of TW202039538A publication Critical patent/TW202039538A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
TW108141960A 2018-11-19 2019-11-19 自殺基因 TW202039538A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US62/769,405 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US62/773,372 2018-11-30
US201962791464P 2019-01-11 2019-01-11
US62/791,464 2019-01-11

Publications (1)

Publication Number Publication Date
TW202039538A true TW202039538A (zh) 2020-11-01

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108141960A TW202039538A (zh) 2018-11-19 2019-11-19 自殺基因

Country Status (18)

Country Link
US (1) US20220023343A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883959A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022513099A (cg-RX-API-DMAC7.html)
KR (1) KR20210093977A (cg-RX-API-DMAC7.html)
CN (1) CN113272320A (cg-RX-API-DMAC7.html)
AU (1) AU2019384115A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009634A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120349A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001300A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007824A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP21044662A (cg-RX-API-DMAC7.html)
IL (1) IL283242A (cg-RX-API-DMAC7.html)
MX (1) MX2021005847A (cg-RX-API-DMAC7.html)
PE (1) PE20211236A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551142A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105238YA (cg-RX-API-DMAC7.html)
TW (1) TW202039538A (cg-RX-API-DMAC7.html)
WO (1) WO2020106619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2011258425B2 (en) * 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
CA2962251A1 (en) * 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
MX2018001568A (es) * 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107312097B (zh) * 2017-07-18 2020-06-16 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
WO2020106619A1 (en) 2020-05-28
EP3883959A1 (en) 2021-09-29
CN113272320A (zh) 2021-08-17
CA3120349A1 (en) 2020-05-28
JP2022513099A (ja) 2022-02-07
IL283242A (en) 2021-07-29
CL2021001300A1 (es) 2022-03-18
BR112021009634A2 (pt) 2021-08-10
PE20211236A1 (es) 2021-07-09
PH12021551142A1 (en) 2021-10-25
CO2021007824A2 (es) 2021-06-30
ECSP21044662A (es) 2021-09-30
KR20210093977A (ko) 2021-07-28
MX2021005847A (es) 2021-09-23
AU2019384115A1 (en) 2021-06-17
SG11202105238YA (en) 2021-06-29
US20220023343A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
JP6995151B2 (ja) synTacポリペプチド及びその使用
JP7717439B2 (ja) 修飾されたt細胞及びその使用方法
US20200115461A1 (en) Compositions and methods for adoptive cell therapies
WO2019118475A1 (en) Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
AU2015357543A1 (en) Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
EP3833682B1 (en) Suicide module compositions and methods
JP2021536245A (ja) 血液中または濃縮pbmc中のリンパ球を遺伝子改変するための方法および組成物
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
JP2022546315A (ja) キメラ抑制性受容体
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
US20250144139A1 (en) Chimeric antigen receptors binding steap1
CN114828862A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
JP7776414B2 (ja) Cd371を標的にする抗原認識受容体およびその使用
TW202144396A (zh) 抑制性嵌合受體架構
TW202309091A (zh) 嵌合受體及其使用方法
KR20210008408A (ko) T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
US20220023343A1 (en) Suicide gene
CA3257650A1 (en) Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
AU2020296197A1 (en) Chimeric protein expressing T-cells
EA045791B1 (ru) Суицидный ген
WO2024254515A2 (en) Systems and methods to direct cellular therapies in vivo to an organ
US20250262300A1 (en) Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2026102195A1 (en) Chimeric tcr constructs targeting bcma and cd19 or cd20 and cd19, and uses of the same
CN120435498A (zh) 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
CN118742319A (zh) 具有抗cd19/抗cd22嵌合抗原受体的基因工程化细胞及其用途